Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Nkarta, Inc.NASDAQ: NKTX
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$3.87M, compared with $192K a year earlier. Trailing-twelve-month accounts payables was -$1.6M. Over 3 fiscal years it compounded at -3.7% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near -$3.87M or moves back toward the trailing-twelve-month quarterly average of -$400.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.46M USD
- Year-over-year change
- +155.1%
- 4-year CAGR
- -3.1%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.46M | +155.1% |
| FY2024 | 2024-12-31 | (4.47M) | -205.8% |
| FY2023 | 2023-12-31 | 4.22M | +53.2% |
| FY2022 | 2022-12-31 | 2.76M | -1.3% |
| FY2021 | 2021-12-31 | 2.79M | — |
Accounts Payables vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +29.9% is the 3rd highest of 8, against a peer median of -59.8%.
- Over three fiscal years its annual growth of -3.7% compares with a peer median of -2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.06M USD | +141.5% | +199.2% | — | |
| LTM Mar 2026 | $5.77M USD | -408.6% | — | 91.4% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.83M USD | -230.5% | — | — |
| LTM Mar 2026 | $3.2M USD | +1050.4% | — | — | |
| LTM Mar 2026 | $2.06M USD | -230.7% | -12.7% | — | |
| LTM Mar 2026 | $1.6M USD | +29.9% | -3.7% | — | |
| LTM Mar 2026 | $903K USD | -59.8% | -2.9% | 4.9% | |
| LTM Mar 2026 | CHF 504.13K CHF | -32.5% | — | — | |
| Peer median (excluding NKTX) | — | -59.8% | -2.9% | 48.2% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 2.24M | 4.61M |
| Deferred Income Tax | 3.24M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.46M | 16.86M | 17.2M | 16.73M | 8.56M |
| Change in Working Capital | (1.64M) | 33.74M | 10.93M | (12.16M) | (435K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.79M | 2.76M | 4.22M | (4.47M) | 2.46M |
| Other Working Capital | (4.44M) | 30.98M | 6.7M | (7.69M) | (2.9M) |
| Other Non-Cash Items | 337K | 3.61M | (2.65M) | 2.29M | 2.65M |
| Operating Cash Flow | (67.93M) | (57M) | (86.16M) | (99.7M) | (88.7M) |
| Capital Expenditures | (5.03M) | (47.11M) | (28.15M) | (4.41M) | (1.21M) |
| Acquisitions (Net) | (37.56K) | 137.58K | 0 | 0 | 0 |
| Purchases of Investments | (227.28M) | (385.89M) | (260.23M) | (406.38M) | (238.57M) |
| Sales of Investments | 264.84M | 248.31M | 367.4M | 281.23M | 340.09M |
| Other Investing Activities | 37.56K | (137.58K) | 0 | 0 | 0 |
| Investing Cash Flow | 32.53M | (184.69M) | 79.02M | (129.56M) | 100.32M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.2M | 217.17M | 691K | 225.07M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.84M | 0 | 1.01M | 0 |
| Financing Cash Flow | 1.2M | 219.01M | 691K | 226.08M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.19M) | (22.68M) | (6.45M) | (3.17M) | 11.76M |
| Free Cash Flow | (72.95M) | (104.11M) | (114.31M) | (104.11M) | (89.91M) |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.